Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.004 +0.024 (+2.47%)
Streaming Delayed Price Updated: 10:54 AM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 69,641
Open 0.9900
Bid (Size) 0.9984 (1,000)
Ask (Size) 1.010 (2,000)
Prev. Close 0.9800
Today's Range 0.9703 - 1.010
52wk Range 0.5501 - 2.260
Shares Outstanding 88,268,078
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill

Performance

YTD
-31.7%
-31.7%
1 Month
-0.6%
-0.6%
3 Month
-17.0%
-17.0%
6 Month
-7.0%
-7.0%
1 Year
-34.8%
-34.8%

More News

Read More
Here are the top movers in Wednesday's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug ↗
Via Chartmill
News headline image
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Here are the top movers in Monday's session. ↗
Via Chartmill

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?
Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?
The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market
What is the current price of Cognition Therapeutics, Inc. - Common Stock?
The current price of Cognition Therapeutics, Inc. - Common Stock is 1.004
When was Cognition Therapeutics, Inc. - Common Stock last traded?
The last trade of Cognition Therapeutics, Inc. - Common Stock was at 09/14/26 10:54 AM ET
What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?
The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 88.64M
How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?
Cognition Therapeutics, Inc. - Common Stock has 89M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.